Core Viewpoint - Otsuka Pharmaceutical has signed a licensing agreement with Harbour BioMed for the exclusive global development and commercialization rights of a candidate drug targeting autoimmune diseases, excluding Greater China, with an upfront payment of $47 million [1][2]. Group 1: Licensing Agreement Details - Otsuka Pharmaceutical will pay an upfront signing fee of $47 million and will also incur additional one-time payments based on development stages and sales targets [2]. - The development costs for the candidate drug will be borne by Otsuka Pharmaceutical as it advances in the autoimmune disease sector [2]. Group 2: Candidate Drug Mechanism - The candidate drug is a "bispecific antibody" that targets two antigens, connecting target cells with immune cells (T cells) to activate T cells, which may help eliminate B cells that produce autoantibodies [2].
大塚制药从中国药企获候选新药开发和销售授权